Journal Club: Navigating Internal Medicine Research

Created using ChatSlide

A recent study published in the NEJM, detailed in Volume 390, No. 6, explores Resmetirom as a promising treatment for non-alcoholic steatohepatitis (NASH). Conducted as a Phase 3, double-blind trial involving participants with fibrosis stages F1B-F3, the study evaluated the efficacy and safety of 80mg and 100mg Resmetirom. Findings indicated improved NASH resolution and better lipid profiles when compared to placebo, with mild gastrointestinal issues noted as the primary adverse effects....